Dominick C. Colangelo
CEO, President & DirectorMr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been Independent Director of Trevi Therapeutics, Inc. since June 29, 2020. Mr. Colangelo served as Chief Accounting Officer at Vericel Corporation since May 7, 2014. He served as Managing Director of Lilly BioVentures and Lilly Venture Funds. Mr. Colangello was responsible for directing Lilly's venture investing activities. He led investments in Xenoport, NexCura, LLC, Zyomyx and Fast Track Systems. He has executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. He joined Lilly in 1995 after practicing tax law in New York and Washington, D.C. He served as the Chief Executive Officer of Promedior, Inc. from January 2009 to May 2012 and also served as its President until May 2012. He served as Consultant of Oscient Pharmaceuticals Corp. since December 2008. He served as an Executive Vice President of Corporate Development and Operations at Oscient Pharmaceuticals Corp. from February 2006 to December 2008 and Senior Vice President for Corporate Development and Operations from January 1, 2005 to February 2006. He led Oscient's licensing, partnering, merger and acquisition and strategic planning activities as well as the corporate quality and compliance, intellectual property and legal teams. He served with Eli Lilly and Company, as founding Managing Director of Lilly Ventures and Director of Strategy and Business Development for Lilly's Diabetes and Growth Disorders Products group. He has been Director of Vericel Corporation since March 2013. He joined Eli Lilly in 1995. He began his career as a practicing attorney. He serves as a Director at NexCura, LLC. He serves on the board of directors of the National Venture Capital Association Medical Industry Group. He served as Director of Promedior, Inc. from January 2009 to May 2012. He served as a Director of Hydra Biosciences Inc., Zyomyx, Inc. and CGI Pharmaceuticals, Inc. He serves Trustee of the National Childhood Cancer Foundation. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.
Positions
- Company NameVericel CorporationStock CodeVCELPositionCEO, President & DirectorColleagues
- RLRobert L. ZerbeIndependent Chairman & Lead Director
- JAJoseph Anthony MaraCFO & Treasurer
- MHMichael HalpinChief Operating Officer
- SCSean C. FlynnChief Legal Officer
- JMJonathan M. HopperChief Medical Officer
- ALAlan L. RubinoIndependent Director
- HMHeidi M. HagenIndependent Director
- KFKevin F. McLaughlinIndependent Director
